Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ONOncolytics Biotech Inc. logo

Oncolytics Biotech Inc. (ONCY)

NASDAQ · Currency in USD
$0.50 ▲ +0.00 (+0.42%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.52 ▲ +0.01 (+2.61%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$0.50
Open
$0.51
Day's Range
$0.49 – $0.51
52 Week Range
$0.44 – $1.32
Volume
375,825
Avg. Volume
1,154,425
Market Cap
$50.41M
Beta (5Y Monthly)
1.16
PE Ratio (TTM)
--
EPS (TTM)
-$0.32
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Oncolytics Biotech Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
29
CEO
Jared Kelly

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.07
DateEst.Actual
Aug 12, 2026-$0.05-$0.08Miss
May 14, 2026-$0.05-$0.08Miss
Mar 30, 2026-$0.06-$0.01Beat
Nov 12, 2025-$0.12-$0.10Beat
Aug 8, 2025-$0.11-$0.05Beat
May 14, 2025-$0.09-$0.06Beat

Analyst view

Rating: Buy
Buy 80% · Hold 20% · Sell 0%

Get free alerts on ONCY and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.